23andMe SPAC Presentation Deck

Transaction Overview 23andMe, a pioneer in consumer health and therapeutic development, expects to enter into a definitive agreement to merge with VG Acquisition Corp. ("Virgin") Implied post-money enterprise value of $3.5 billion Transaction to be funded through a combination of Virgin's $509 million Cash in Trust and $250 million of committed PIPE financing Net proceeds used to fund cash to balance sheet for growth initiatives Current shareholders of 23andMe expected to maintain 81% pro forma ownership Sir Richard Branson and Anne Wojcicki to invest $25 million each 23and Me Confidential and Proprietary Information 36

View entire presentation